Rallis Chris A's Form 4 filing
Fennec Pharmaceuticals Inc. (FENC) · filed Apr 11, 2025
- Accession no.
- 0001415889-25-010574
- Filed
- Apr 11, 2025
- Trade date
- Apr 11, 2025
- Filing delay
- Same day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $6.97K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rallis Chris ACIK 0001185945 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 11, 2025 | Common Shares | MOption exerciseAcquired | +2,173 | $2.30 | +$4,997.9 | 55,193 | Direct | |
| Apr 11, 2025 | Common Shares | SSaleDisposed | −1,409 | $4.95 | −$6,974.55 | 53,784 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 11, 2025 | Options | MOption exerciseDisposed | −2,173 | $2.30 | −$4,997.9 | 180,533 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.